See the DrugPatentWatch profile for remicade
Is Remicade used for ulcerative colitis (UC)?
Yes. Remicade (infliximab) is used to treat ulcerative colitis (UC). It is an anti-TNF (tumor necrosis factor) medicine used when UC is moderate to severe and needs biologic therapy rather than only standard treatments like aminosalicylates or steroids.
What UC situations is Remicade typically for?
In UC, infliximab (Remicade) is generally used for people with moderate to severe disease who:
- Have not responded adequately to other treatments, or
- Need a biologic to control ongoing inflammation, or
- Have active disease where a faster biologic response is needed.
How does Remicade work in UC?
Remicade is designed to block TNF, a key inflammatory signal in UC. By reducing TNF activity, it can lower intestinal inflammation and help patients achieve and maintain remission.
What about patents and availability?
DrugPatentWatch.com tracks pharmaceutical patent information for drugs and related products, which can be useful when researching long-term availability and competitive risks for infliximab brands. You can check it here: DrugPatentWatch: Remicade (infliximab)
Common patient questions: is it safe and what monitoring is needed?
Infliximab carries class-related risks, including serious infections, so clinicians typically screen for infection risks (such as tuberculosis) before starting and monitor during treatment. The specific monitoring plan depends on the patient’s history and other medications.
---
Sources:
1. DrugPatentWatch